Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.35 |
| ▸ | GOT1 | P17174 | 1/20 | 0.35 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.35 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4703310 | 0.84 | CYP1A2 (0.39) | OPRL1TRPA1AADATCYP1A2CYP2D6 | |
| SCHEMBL6096856 | 0.84 | SCN9A (0.42) | OPRL1DPP4SCN9AAADAT | |
| SCHEMBL4420923 | 0.81 | OPRL1 (0.42) | OPRL1SCN9ATRPA1AADAT | |
| SCHEMBL7471730 | 0.81 | OPRL1 (0.42) | OPRL1SCN9ATRPA1AADAT | |
| Trifluoroacetic Acid SCHEMBL6097700 | 0.75 | SCN9A (0.47) | SCN9A | |
| SCHEMBL7038910 | 0.73 | ALDH1A1 (0.43) | SCN9AAADATGOT1KYAT1KYAT3 | |
| SCHEMBL4995780 | 0.71 | OPRL1 (0.41) | OPRL1SCN9ATRPA1CYP1A2CYP2D6 | |
| SCHEMBL8025052 | 0.71 | OPRL1 (0.41) | OPRL1SCN9ATRPA1CYP1A2CYP2D6 | |
| SCHEMBL13893712 | 0.70 | MAOA (0.39) | SCN9ATRPA1 | |
| SCHEMBL7330405 | 0.70 | TRPA1 (0.39) | OPRL1SCN9ATRPA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001901-B2 | Tetrazolylpropionamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | claimed |
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-29 | — | — | US | claimed |
| US-7001901-B2 | Tetrazolylpropionamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | APP, APBA1, DNPEP | OPRL1 436/4885DPP4 696/4885SCN9A 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.